loader

World Tenders & Procurement Opportunities

Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a Paragraph 8 of the Social Code Book V by means of an open-house model for the active ingredient tiotropium bromide (ATC code according to WHO: R03BB04) -684322

World Biggest Tenders Source

This tender with title Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a Paragraph 8 of the Social Code Book V by means of an open-house model for the active ingredient tiotropium bromide (ATC code according to WHO: R03BB04) -684322 has been published on Bidding Source portal dated 15 Nov 2024 for the country of Germany. It has been categorized on Pharmaceutical products. For similar tenders you can see tenders mentioned below of this page.

General Information

Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a Paragraph 8 of the Social Code Book V by means of an open-house model for the active ingredient tiotropium bromide (ATC code according to WHO: R03BB04) -684322
Invitation for Bids
Germany
15 Nov 2024
31 Dec 2026
English
Pharmaceutical products

For viewing full details of tenders, you should Log in to your account. If not registered yet, Please Register Now

Or Request a call back now and one of our representatives will contact you. Contact us

Similar Tenders

Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a Paragraph 8 of the Social Code Book V by means of an open-house model for the active ingredient tocilizumab (ATC code according to WHO: L04AC07) -683491 Germany Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a Paragraph 8 of the Social Code Book V by means of an open-house model for the active ingredient brinzolamide/timolol (official ATC code: S01ED67) -683594 Germany Contract Manufacturing Organisation (CMO) - Remedi4all - PR798936-3640-I -685134 Germany Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a Paragraph 8 of the Social Code Book V by means of an open-house model for the active ingredient golimumab (ATC code according to WHO: L04AB06) -684421 Germany Pharmaceutical discount agreements from 01.01.2025 for various active ingredients within the framework of an open-house procedure -683646 Germany Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a Paragraph 8 of the Social Code Book V by means of an open-house model for the active ingredient infliximab for subcutaneous injection (ATC code according to WHO: L04AB02) -684145 Germany Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a Paragraph 8 of the Social Code Book V by means of an open-house model for the active ingredient rotigotine (ATC code according to WHO: N04BC09) -684657 Germany Conclusion of non-exclusive discount agreements pursuant to Section 130a Paragraph 8/130c Paragraph 1 SGB V for medicinal products containing the active ingredient levothyroxine sodium (H03AA01) within the framework of a so-called open-house model. - 675443 Germany Conclusion of non-exclusive discount agreements pursuant to Section 130a Paragraph 8 SGB V for the active ingredients mentioned with the possibility of conclusion within the framework of the so-called open house procedure. - 683215 Germany Pharmaceutical products – Patent_80.2 - 681458 Germany
No. 12, 1 st floor, Block B2, EGS Business Park, World Trade Center, Bakirkoy - Istanbul - Turkey
info@biddingsource.com
24 X 7 online support
TOP
For viewing latest tenders published for your business in all over the World: Sign in Join free
For accessing full details of Tenders, Kindly choose the Plan that works for you: View Subscription Plans